image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 18.68
-0.691 %
$ 1.09 B
Market Cap
13.94
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one EMBC stock under the worst case scenario is HIDDEN Compared to the current market price of 18.7 USD, Embecta Corp. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one EMBC stock under the base case scenario is HIDDEN Compared to the current market price of 18.7 USD, Embecta Corp. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one EMBC stock under the best case scenario is HIDDEN Compared to the current market price of 18.7 USD, Embecta Corp. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
1.12 B REVENUE
0.21%
167 M OPERATING INCOME
-24.70%
78.3 M NET INCOME
11.22%
35.7 M OPERATING CASH FLOW
-47.27%
-15.8 M INVESTING CASH FLOW
40.38%
-73.4 M FINANCING CASH FLOW
-50.72%
286 M REVENUE
4.99%
26.2 M OPERATING INCOME
-53.13%
14.6 M NET INCOME
-0.68%
26.6 M OPERATING CASH FLOW
1366.67%
0 INVESTING CASH FLOW
100.00%
-36.6 M FINANCING CASH FLOW
-218.26%
Balance Sheet Embecta Corp.
image
Current Assets 761 M
Cash & Short-Term Investments 268 M
Receivables 248 M
Other Current Assets 246 M
Non-Current Assets 524 M
Long-Term Investments 0
PP&E 290 M
Other Non-Current Assets 234 M
Current Liabilities 374 M
Accounts Payable 91 M
Short-Term Debt 12.9 M
Other Current Liabilities 270 M
Non-Current Liabilities 1.65 B
Long-Term Debt 1.6 B
Other Non-Current Liabilities 54.1 M
EFFICIENCY
Earnings Waterfall Embecta Corp.
image
Revenue 1.12 B
Cost Of Revenue 388 M
Gross Profit 735 M
Operating Expenses 568 M
Operating Income 167 M
Other Expenses 88.5 M
Net Income 78.3 M
RATIOS
65.46% GROSS MARGIN
65.46%
14.85% OPERATING MARGIN
14.85%
6.97% NET MARGIN
6.97%
-10.61% ROE
-10.61%
6.09% ROA
6.09%
35.32% ROIC
35.32%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Embecta Corp.
image
Net Income 78.3 M
Depreciation & Amortization 36.2 M
Capital Expenditures -15.8 M
Stock-Based Compensation 26.3 M
Change in Working Capital -47.7 M
Others 96.7 M
Free Cash Flow 19.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Embecta Corp.
image
Wall Street analysts predict an average 1-year price target for EMBC of $19.3 , with forecasts ranging from a low of $12 to a high of $26 .
EMBC Lowest Price Target Wall Street Target
12 USD -35.76%
EMBC Average Price Target Wall Street Target
19.3 USD 3.50%
EMBC Highest Price Target Wall Street Target
26 USD 39.19%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.15 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Embecta Corp.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
32.5 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
11 months ago
Feb 12, 2024
Bought 32.5 K USD
Melcher David F
Director
+ 2000
16.25 USD
1 year ago
Sep 08, 2023
Bought 98.3 K USD
Melcher David F
Director
+ 6233
15.7662 USD
1 year ago
Aug 10, 2023
Bought 109 K USD
Kurdikar Devdatt
President and CEO
+ 5000
21.81 USD
1 year ago
Aug 10, 2023
Bought 102 K USD
Mann Jeffrey Z
SVP, GC, Head Corp. Dev., Secy
+ 4700
21.67 USD
1 year ago
Aug 10, 2023
Bought 100 K USD
Elguicze Jacob
SVP and CFO
+ 4625
21.6637 USD
1 year ago
Feb 15, 2023
Bought 102 K USD
Melcher David F
Director
+ 3100
32.925 USD
1 year ago
Feb 15, 2023
Bought 101 K USD
Melcher David F
Director
+ 3100
32.51 USD
7. News
3 Stocks Trading Near 52-Week High With Room to Rise Further Investors target stocks that have been on a bullish run lately. Stocks like EMBC, NFG and REVG are seeing price strength and the momentum is likely to continue. zacks.com - 1 week ago
3 Medical Services Stocks to Buy to Counter Labor Shortage Woes The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. DOCS, BTSG and EMBC are set to gain the most. zacks.com - 2 weeks ago
4 Best-Bargain PEG Stocks That Value Investors Love Here are four stocks that fit our screening criteria. These are GAP, EMBC, BLBD and ZIM. zacks.com - 3 weeks ago
embecta to Participate at the 43rd Annual J.P. Morgan Healthcare Conference PARSIPPANY, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 7:30 a.m. PT / 10:30 a.m. ET. globenewswire.com - 1 month ago
New Initiatives Expected To Make Embecta More Profitable Embecta Corp.'s Q4 results showed significant net income and EPS growth as well as profitability plans, and drove up the share price. The company announced a restructuring plan to streamline operations, reduce costs by up to $65 million annually, and discontinue its insulin patch pump program. Embecta aims to strengthen its core business, expand its GLP-1 therapies portfolio, and reduce debt, positioning it for profitable growth in fiscal 2025. seekingalpha.com - 1 month ago
New Strong Buy Stocks for December 2nd EMBC, TOST, MNDY, NTRS and MANU have been added to the Zacks Rank #1 (Strong Buy) List on December 2, 2024. zacks.com - 1 month ago
Best Value Stocks to Buy for December 2nd EMBC, BLBD and ENVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 2, 2024. zacks.com - 1 month ago
Best Income Stocks to Buy for December 2nd CTBI and EMBC made it to the Zacks Rank #1 (Strong Buy) income stocks list on December 2, 2024. zacks.com - 1 month ago
Overlooked Stock: EMBC Bad news is good news? Appears to be the case for medical device company Embecta (EMBC) as shares soared after it stopped its insulin patch pump program. youtube.com - 1 month ago
Embecta Corp. (EMBC) Q4 2024 Earnings Call Transcript Embecta Corp. (NASDAQ:EMBC ) Q4 2024 Earnings Conference Call November 26, 2024 8:00 AM ET Company Participants Pravesh Khandelwal - VP of IR Dev Kurdikar - President and CEO Jake Elguicze - CFO Conference Call Participants Marie Thibault - BTIG Operator Good day, and welcome to the Embecta Fourth Quarter of Fiscal Year 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. seekingalpha.com - 1 month ago
Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps On Tuesday, Embecta Corp EMBC posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago. benzinga.com - 1 month ago
Embecta Corp. (EMBC) Tops Q4 Earnings and Revenue Estimates Embecta Corp. (EMBC) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to earnings of $0.59 per share a year ago. zacks.com - 1 month ago
8. Profile Summary

Embecta Corp. EMBC

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 1.09 B
Dividend Yield 0.00%
Description Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Contact 300 Kimball Drive, Parsippany, NJ, 07054 https://www.embecta.com
IPO Date March 22, 2022
Employees 2200
Officers Ms. Colleen Riley Senior Vice President & Chief Technology Officer Mr. Tom Blount Senior Vice President & President of North America Mr. Shaun Curtis Senior Vice President of Global Manufacturing & Supply Chain Ms. Jean M. Casner Senior Vice President & Chief Human Resources Officer Mr. Jacob P. Elguicze Senior Vice President & Chief Financial Officer Mr. Jeffrey Z. Mann Senior Vice President, General Counsel, Head of Business Development & Corporate Secretary Mr. Pravesh Khandelwal Vice President & Head of Investor Relations Ms. Ginny Blocki Senior Vice President of Global Marketing & Product Management Mr. Devdatt Kurdikar President, Chief Executive Officer & Director Mr. Slobodan Radumilo Senior Vice President & President of International